1. Home
  2. BFRI vs PHGE Comparison

BFRI vs PHGE Comparison

Compare BFRI & PHGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Biofrontera Inc.

BFRI

Biofrontera Inc.

HOLD

Current Price

$0.82

Market Cap

8.4M

Sector

Health Care

ML Signal

HOLD

Logo BiomX Inc. COmmon Stock

PHGE

BiomX Inc. COmmon Stock

HOLD

Current Price

$3.93

Market Cap

9.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BFRI
PHGE
Founded
1997
2015
Country
United States
Israel
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
8.4M
9.5M
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
BFRI
PHGE
Price
$0.82
$3.93
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
1
Target Price
$2.75
$26.00
AVG Volume (30 Days)
125.9K
2.1M
Earning Date
03-20-2026
03-24-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$37,164,000.00
N/A
Revenue This Year
$11.37
N/A
Revenue Next Year
$10.96
N/A
P/E Ratio
N/A
N/A
Revenue Growth
5.11
N/A
52 Week Low
$0.54
$1.50
52 Week High
$1.20
$22.06

Technical Indicators

Market Signals
Indicator
BFRI
PHGE
Relative Strength Index (RSI) N/A N/A
Support Level N/A N/A
Resistance Level N/A N/A
Average True Range (ATR) 0.00 0.00
MACD 0.00 0.00
Stochastic Oscillator 0.00 0.00

Price Performance

Historical Comparison
BFRI
PHGE

About BFRI Biofrontera Inc.

Biofrontera Inc is a United States-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy. The Company's licensed products, which include Ameluz as well as the BF-RhodoLED and RhodoLED XL lamps (together, the RhodoLED Lamps), are used for the treatment of actinic keratoses (AKs), which are pre-cancerous skin lesions.

About PHGE BiomX Inc. COmmon Stock

BiomX Inc is engaged in developing both natural and engineered phage cocktails and personalized treatments designed to target and destroy harmful bacteria in chronic diseases, including cystic fibrosis and diabetic foot osteomyelitis. It discovers and validates proprietary bacterial targets and customizes phage compositions against these targets, and applies its BOLT (BacteriOphage Lead to Treatment) platform to customize phage compositions against these targets. BX004 is its therapeutic phage product candidate under development for chronic pulmonary infections caused by Pseudomonas aeruginosa, or P. aeruginosa, a main contributor to morbidity and mortality in patients with CF. Its BX211 - Treatment of Diabetic Foot Osteomyelitis (DFO).

Share on Social Networks: